Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with M
Go back to Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with M| StemCells, Inc. (NASDAQ: TEM) | Delayed: 78.03 +0.19 (0.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $77.84 | 52 Week High | $0.45 | |||
| Open | $79.08 | 52 Week Low | $0.37 | |||
| Day High | $80.25 | P/E | N/A | |||
| Day Low | $77.13 | EPS | $-0.31 | |||
| Volume | 5,639,683 | |||||
